R&D; investment dips to 10% of revenue since peak of 13.5% in FY17 Investments in R&D; was largely flattish in FY20 to Rs15.5bn, that is 10% of sales down from 11% in FY19 as part of cost optimization program. We highlight major products/pipeline spend of R&D;: Lupin received approval for Nepexto (biosimilar Enbrel) in Europe...